The invention discloses a 1/2 water Cefradine compound and a preparation method thereof, which contains 1/2 mole of water per mole of cefradine. The X-ray diffraction pattern has characteristic peaks at the diffraction angle 2theta of 7.25+0.2 degree, 10.98+0.2 degree, 14.53+0.2 degree, 16.28+0.2 degree, 17.80+0.2 degree, 19.38+0.2 degree, 20.21+0.2 degree, 22.06+0.2 degree and 22.90+0.2 degree. The crude Cefradine was dissolved in water, adsorbed by activated carbon, added with dissolving agent and crystallized to obtain cefradine crystal. The crystal was dissolved in the mixed solution of water and methanol, added with seed and crystallized to obtain 1/2 of cefradine hydrochloride compound. The operation is simple, the reactants are readily available, the reaction conditions are mild and the yield is high. The 1/2 water Cefradine compound of the invention has good particle size distribution, good fluidity, low impurity content and good stability, and has a wider application prospect.
【技术实现步骤摘要】
一种1/2水头孢拉定化合物
本专利技术属于化学工程医药结晶
,涉及一种1/2水头孢拉定化合物及其制备方法。
技术介绍
头孢拉定(Cefradine)属于第一代头孢菌素,化学名为(6R,7R)-7-[(R)-2-氨基-2-(l,4-环己二烯-1-基)乙酰氨基]-3-甲基-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸。结构式如下:头孢拉定为美国施贵宝制药公司于1972年研究成功的半合成头孢类抗生素,并于20世纪70年代进入医药市场。头孢拉定在临床上对呼吸道感染症、尿路感染、皮肤及软组织感染、胃肠道感染以及骨和关节的感染、败血症、心内膜炎等有较好的疗效和高度安全性,临床应用极为广泛。目前国内的头孢拉定同国外同类产品相比存在粒度分布不均、流动性差、杂质偏高、稳定性较差等问题。而这些问题主要是由于制备方法落后导致的。这些问题的存在一方面导致产品质量较差且批间不稳定,另外还在一定程度上导致生产成本的提高及原材料的浪费。为解决上述问题,制备一种粒度分布好、流动性好、杂质含量低、性质稳定的头孢拉定显得尤为重要。本专利技术将药物晶体超分子组装机理创造性地 ...
【技术保护点】
1.一种1/2水头孢拉定化合物,其特征在于,每摩尔头孢拉定含1/2摩尔水,分子式:C16H19N3O4S·1/2H2O,分子量:358.40,结构式如下:
【技术特征摘要】
1.一种1/2水头孢拉定化合物,其特征在于,每摩尔头孢拉定含1/2摩尔水,分子式:C16H19N3O4S·1/2H2O,分子量:358.40,结构式如下:2.一种药物组合物,其特征在于包含权利要求1所述...
还没有人留言评论。发表了对其他浏览者有用的留言会获得科技券。